VA/DoD Suicide Risk Guideline (2024): What Changed, What Didn’t, and What It Means for Veteran Care

Author: Michael Dionne, DNP, PMHNP-BC | Reforge Psychiatry Updated: April 27, 2026

TL;DR

• The VA DoD suicide risk guideline Version 3.0 (April 2024) adopted a stricter GRADE evidence methodology, which reclassified many interventions even though their underlying clinical evidence did not change.
• CAMS, DBT, lithium for suicide prevention, and ketamine-for-SI in major depression were all affected by the methodology shift. Most moved from Weak for or similar to Neither for nor against.
• The methodology change is not a clinical repudiation. It reflects what survives a higher evidentiary bar, not what stopped working.
• Recommendation 12 — ketamine infusion for suicidal ideation with major depression — retained a Weak for grade, making it one of the strongest VA/DoD-endorsed citations in the document for a specific indication.
• The Rocky Mountain MIRECC Risk Stratification Table, Joint Commission requirements, and CARF accreditation standards remain operationally binding regardless of how any given intervention is graded.

In April 2024, the VA and DoD released Version 3.0 of their joint clinical practice guideline for assessment and management of patients at risk for suicide. The document landed with relatively little public attention for something that governs the scaffolding of suicide care inside the two largest integrated health systems in the United States.

Clinicians who actually read the guideline came away with a problem. Several interventions that had been endorsed in earlier versions now carried weaker grades. CAMS. DBT. Lithium for suicide prevention. Ketamine for suicidal ideation. On first read, this looks like the evidence base fell apart. It did not.

What happened is a methodology shift — the guideline panel moved to a stricter application of the GRADE evidence framework, which reweights what counts as a sufficiently powered recommendation. Many interventions whose clinical data have not changed in a decade nonetheless received lower grades under the new framework. This article walks through what actually changed, what did not, and what the guideline means for veteran care on the ground.

What GRADE Is and Why the Methodology Shift Matters

Quick answer: GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) is a framework for rating the quality of clinical evidence and the strength of resulting recommendations. Version 3.0 of the VA/DoD suicide risk guideline applied GRADE more strictly than Version 2.0 did.

Common misunderstanding: A Neither for nor against grade is often read as “this doesn’t work” or “this shouldn’t be used.” GRADE does not support that reading. A Neither for nor against grade reflects that the available evidence is insufficient to make a firm recommendation either direction — not that the intervention is ineffective or contraindicated.

Methodological reality: GRADE weights several factors in producing a recommendation: risk of bias, inconsistency across studies, indirectness (did the studies measure the outcome we care about in the population we care about), imprecision, and publication bias. Many suicide-prevention interventions have been studied in smaller trials, in narrower populations, or with proxy outcomes (suicidal ideation reduction rather than suicide completion). Under a strict GRADE application, these features downgrade the recommendation even when the interventions appear to work in practice.

In practice: When a clinician reads Neither for nor against lithium for reduction of suicide risk in patients with mood disorders, the correct translation is that the evidence base does not meet the stricter GRADE bar, but that does not mean the clinician cannot use lithium in appropriate patients with appropriate monitoring. The guideline explicitly notes that clinical judgment remains central.

Interventions That Moved Under the New Methodology

Quick answer: CAMS, DBT, lithium for suicide prevention, and ketamine-for-SI (in populations other than MDD specifically) saw grade changes. In most cases, the underlying clinical evidence did not change between guideline versions.

Common misunderstanding: Some have interpreted the grade changes as VA/DoD signaling away from these interventions. That is not what the guideline says. The authors were explicit that methodology, not new data, drove most of the reclassifications.

Clinical reality: Collaborative Assessment and Management of Suicidality (CAMS) — an evidence-based structured framework for working with suicidal patients — moved to a weaker grade despite a body of literature including multiple randomized controlled trials and implementation studies. Dialectical Behavior Therapy (DBT), long considered a gold-standard treatment for patients with recurrent self-harm and borderline personality disorder, has also moved. Lithium’s anti-suicidal effect — one of the most studied pharmacological findings in psychiatry — was downgraded. These changes reflect what the new methodology can formally endorse, not a change in clinical reality. CAMS-care.com continues to publish ongoing trial data. DBT remains a core training requirement for many residencies. Lithium is still prescribed by clinicians who understand its narrow therapeutic window and its evidence base.

In practice: Clinicians treating veterans at elevated suicide risk should continue to use interventions with strong clinical track records, regardless of GRADE grade. The guideline itself supports this. What the grade changes do require is clearer documentation of the clinical reasoning when deploying an intervention that now carries a weaker recommendation. A CAMS-trained provider using CAMS with an appropriate patient is not off-guideline. The provider is using a clinically supported intervention whose documentation framework (the Suicide Status Form) is among the most structured in the field.

What Did Not Change: Recommendations 12 and 13 on Ketamine

Quick answer: Recommendation 12 of the 2024 guideline retained a Weak for grade for ketamine infusion therapy in patients with suicidal ideation and major depressive disorder. This is one of the stronger VA/DoD-endorsed citations for a specific indication in the document. Recommendation 13, which addresses ketamine and esketamine for preventing suicide attempts, received a Neither for nor against grade.

Common misunderstanding: Weak for sounds lukewarm. In GRADE terminology, Weak for is a positive recommendation — it signals that the intervention’s benefits likely outweigh harms in appropriate patients, with acknowledged uncertainty. It is not a hedge against use; it is a signal to use the intervention with clinical judgment and patient-specific considerations.

Clinical reality: The retention of Weak for on Recommendation 12 is significant because ketamine’s evidence base for suicidal ideation specifically — as distinct from treatment-resistant depression more broadly — is narrower and more recent. The VA/DoD panel reviewed the available data and concluded the methodology supported a positive recommendation for ketamine infusion when the indication is SI with MDD. The verbatim recommendation reads: “We suggest offering ketamine infusion as an adjunctive treatment for short-term reduction in suicidal ideation in patients with the presence of suicidal ideation and major depressive disorder.”

Recommendation 13 is the important counterpart. It states: “There is insufficient evidence to recommend for or against ketamine infusions or esketamine to reduce the risk of suicide or suicide attempts.” This distinction matters — ketamine has a positive grade for reducing suicidal ideation in a specific population (Rec 12), but insufficient evidence to recommend it for preventing suicide attempts as an outcome (Rec 13). Clinicians should cite the correct recommendation for the correct indication and not conflate the two.

In practice: Recommendation 12 does not mean every suicidal patient with depression should receive ketamine. It means that ketamine infusion is a supported modality for the SI+MDD indication, and the grade is strong enough to cite in consultation notes, referral documentation, and patient counseling. For clinicians at institutions requiring guideline-concordant care justifications, Recommendation 12 is the citation. Recommendation 13 is the appropriate reference when the question is about suicide attempt prevention specifically — and the answer there is that the evidence is not yet sufficient for a recommendation either way.

What Remains Operationally Binding Regardless of Grade

Quick answer: The Rocky Mountain MIRECC Clinical Risk Stratification Table, Joint Commission suicide risk reduction standards (NPSG 15.01.01), and CARF behavioral health accreditation requirements continue to govern day-to-day practice, independent of any given intervention’s GRADE grade.

Common misunderstanding: Some clinicians have read the 2024 guideline as a signal that risk stratification frameworks are optional. They are not.

Operational reality: The Rocky Mountain MIRECC Risk Stratification Table, developed through the VA’s Mental Illness Research, Education, and Clinical Center system, remains an operationally endorsed framework within VA settings and has been widely adopted outside the VA as well. The Joint Commission’s National Patient Safety Goal 15.01.01 requires structured suicide risk assessment and reduction interventions for patients being treated for behavioral health conditions. CARF accreditation standards impose parallel documentation and intervention requirements for accredited behavioral health programs. These standards are not negated by the 2024 guideline’s grade changes. An intervention graded Neither for nor against by the VA/DoD can still be the right intervention under Joint Commission or CARF standards if it meets the program’s structured risk management criteria.

In practice: Clinicians and program directors should continue to treat the MIRECC table, NPSG 15.01.01, and CARF standards as the operational baseline. The VA/DoD guideline is a valuable reference for evidence-grading — but it is not the only binding document, and it is not the final word on what structured suicide risk management looks like in an accredited clinical environment. The mirecc.va.gov/visn19 site remains the primary public-facing source for the stratification table.

How to Read the 2024 Guideline as a Practicing Clinician

Quick answer: Treat the guideline as an evidence-mapping document that reflects the state of GRADE-quality research, not as a clinical directive that overrides judgment, accreditation requirements, or established risk management frameworks.

Clinical reality: A clinician reading Version 3.0 for the first time should do three things. First, note which recommendations changed and which did not — the “did not change” list, including Recommendation 12, is the shorter, higher-signal column. Second, pair the guideline with the MIRECC table and whichever accreditation standards apply to your program; together, they form the operational framework. Third, adjust documentation accordingly. An intervention that now grades Neither for nor against is not off-limits, but its use benefits from clearer clinical reasoning in the record — specifically: why this intervention for this patient, what alternatives were considered, what monitoring plan accompanies it.

In practice: For practices treating veterans, the combination of CAMS training plus structured risk stratification plus selective use of guideline-supported interventions (including Recommendation 12 for appropriate patients) meets or exceeds the standard of care that emerges from the full VA/DoD guideline plus Joint Commission plus CARF. That combination is also the documentation posture that holds up best under review.

Key Takeaways

• The 2024 VA/DoD suicide risk guideline applied a stricter GRADE methodology, reclassifying several interventions without a change in underlying clinical evidence.
• CAMS, DBT, lithium, and ketamine-for-SI (in broader populations) moved to weaker grades. This does not mean they stopped working.
• Recommendation 12 retained a Weak for grade for ketamine infusion in SI with major depressive disorder — a citable, positive VA/DoD endorsement.
• Recommendation 13 found insufficient evidence to recommend for or against ketamine or esketamine for suicide attempt prevention — a distinct indication from Rec 12.
• The MIRECC Risk Stratification Table, Joint Commission NPSG 15.01.01, and CARF standards remain operationally binding regardless of grade changes.
• The guideline is an evidence-mapping document. Structured risk assessment, clinical judgment, and accreditation standards still govern day-to-day practice.

FAQs

The Bottom Line

The 2024 VA DoD suicide risk guideline is a better evidence-mapping document than its predecessor. It is also more easily misread. A clinician who mistakes Neither for nor against for “don’t use this” is going to narrow their clinical toolkit for the wrong reasons. The right read is methodological — a stricter bar, not a repudiation — and the operational picture continues to be shaped at least as much by MIRECC, Joint Commission, and CARF as by GRADE grades. If you’re treating veterans at elevated suicide risk and want to talk through how this guideline applies to your clinical setting, I’m happy to connect.

This article is for educational purposes only and does not constitute medical advice. Always consult a licensed provider for guidance specific to your situation. If you are in crisis, call or text 988 (Veterans: press 1) or go to your nearest emergency department.

This post is intended as a clinical reference for licensed providers. CE credit is not currently available; newsletter subscribers will be notified if accreditation is added.

Michael Dionne, DNP, PMHNP-BC, is the founder of Reforge Psychiatry. He is a board-certified psychiatric mental health nurse practitioner and U.S. Army veteran specializing in PTSD treatment, medication management, and telehealth psychiatry for veterans and first responders. Licensed in California, New Hampshire, New York, Illinois, and Idaho.

References

1. U.S. Department of Veterans Affairs & U.S. Department of Defense. (2024). VA/DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide, Version 3.0. https://www.healthquality.va.gov/guidelines/MH/srb/VADoD-CPG-Suicide-Risk-Full-CPG-2024_Final_508.pdf
2. Guyatt, G. H., et al. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924–926. https://pubmed.ncbi.nlm.nih.gov/18436948/
3. Schünemann, H. J., et al. (Eds.). (2013). GRADE Handbook: Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. https://gdt.gradepro.org/app/handbook/handbook.html
4. Rocky Mountain MIRECC for Veteran Suicide Prevention. Therapeutic Risk Management — Risk Stratification Table. https://www.mirecc.va.gov/visn19/trm/
5. The Joint Commission. National Patient Safety Goal 15.01.01 — Reduce the risk of suicide. https://www.jointcommission.org/standards/national-patient-safety-goals/
6. Jobes, D. A. (2023). Managing Suicidal Risk: A Collaborative Approach (3rd ed.). Guilford Press. CAMS-care clinical resources: https://cams-care.com/resources/
7. Jobes, D. A., et al. (2017). A randomized controlled trial of the Collaborative Assessment and Management of Suicidality versus enhanced care as usual with suicidal soldiers. Psychiatry, 80(4), 339–356. https://pubmed.ncbi.nlm.nih.gov/29466107/
8. Wilkinson, S. T., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150–158. https://pubmed.ncbi.nlm.nih.gov/28969441/

Related Reading

• PTSD Disability Rating: What Your Psychiatric Documentation Actually Controls
• The VA Almost Changed How Medication Affects Your Disability Rating — Here’s What Actually Happened
• The Complete Guide to PTSD Treatment for Veterans